Cell therapies involve the administration of cells or gene-modified cells into patients to treat disease and injury.
Thus, this market brief presents the
average price range for each category, as well as the
exact price range for each category based on the globally approved products (including
high and low outliers).
Last year in 2024, these products generated an astounding $13 billion in revenue, establishing them as a commercially significant market segment.
This 61-page market brief includes market approvals and pricing data from the:- U.S. FDA
- European EMA
- Chinese NMPA
- Japanese PMDA
- South Korean MFDS
- Australian TGA
- Indian CDSCO
- And other leading regulatory agencies worldwide
It reveals:- Market pricing for all globally approved cell therapies known worldwide
- The identity and type of cell therapies approved worldwide
- Factors influencing the market pricing of cell therapies
- Categories of cell therapy products and their price ranges
- Novel payment and financing models emerging worldwide
This information took BioInformant's experienced team of analysts
hundreds of hours to aggregate, required
translators to interpret pricing data across
numerous languages, and
entailed calls, emails, and outreach to cell therapy developers
worldwide.
Whether you are developing cell therapies, investing in them, supplying the raw materials, or securing IP within this field, this market brief will deliver critical insights you can’t afford to miss.
Because we've received numerous requests, for 24 hours more, you can
claim this report for an unusual 50% off:
Remember to act fast, because this offer this Friday, May 23rd, at midnight.
Be Great,
The BioInformant Team
p.s. Interested in other areas, like iPS cells, MSCs, CAR-T, Regenerative Medicine, or beyond? Explore the
BioInformant Shop.
